132 results on '"Pirker, R."'
Search Results
2. Hyperprogression of Merkel cell carcinoma after avelumab treatment
3. JICC01.07 Oral VEGFR Inhibitor Monotherapy for Lung Cancer: Should We or Should We Not?
4. SP-0759: Immunotherapy approaches to advanced lung cancer
5. Conquering lung cancer: current status and prospects for the future
6. New concepts in pulmonary oncology
7. Bronchialkarzinom
8. Zytostatische Chemotherapie
9. PC05.03 ICIs for Patients with Immune-Related Comorbidity
10. Interim results of an ongoing Project to eliminate chronic hepatitis C in People who inject drugs (PWID) with ongoing intravenous drug use and a high risk of non-adherence to direct-acting antivirals (DAA) in Vienna
11. Expression of the MDR1 Gene and Treatment Outcome in Acute Nonlymphocytic Leukemia
12. Strategien zur Überwindung der erworbenen EGFR-TKI-Resistenz durch T790M spezifische Substanzen am Beispiel von Osimertinib
13. P2.09-004 PD-L1 Protein Expression Is Negative Prognostic Factor in Malignant Pleural Mesothelioma in Central Europe
14. MS 20.02 Value-Based Judgment in Advanced NSCLC: The European Perspective
15. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer
16. Neoadjuvante Chemo- oder Chemoradiotherapie gefolgt von Resektion bei lokal fortgeschrittenem Nicht-Kleinzelligem Lungekarzinom – eine retrospektive institutionelle Studie
17. 3109 nab-Paclitaxel (nab-P) plus carboplatin (C) as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC): Clinical outcomes by treatment cycle
18. Trimodality Therapy Including Radical Resection for Pancoast Tumors: T4 is not a Contraindication for Radical Surgery
19. Short-Term In Vitro Sensitivity Testing in Acute Leukemia
20. Molekulargenetische Untersuchungen bei fortgeschrittenem nicht-kleinzelligem Lungenkarzinom: praktische Relevanz
21. Prognostic and Predictive Biomarkers for Act (Adjuvant Chemotherapy) in Resected Non-Small Cell Lung Cancer (R-Nsclc): Lace-Bio
22. Effectiveness of Darbepoetin Alfa (Da) for Chemotherapy-Induced Anaemia (Cia) When Initiated at Haemoglobin (Hb) ≤10 G/Dl
23. Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients
24. Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient
25. Docetaxel Therapie im fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom (NSCLC) - Resultate einer Observationsstudie mit Fokus auf Verbesserung von Tumor-assoziierten Symptomen unter Therapie
26. Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses
27. Relationship Between EGFR Expression Level, EGFR Mutation Status and the Efficacy of Chemotherapy Plus Cetuximab in Flex Study Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
28. Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study
29. Third CECOG consensus on the systemic treatment of non-small-cell lung cancer
30. High D-dimer levels are associated with poor prognosis in cancer patients
31. 9000 ORAL Epidermal Growth Factor Receptor (EGFR) Expression as a Predictive Biomarker of Survival in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving First-Line Therapy With Cetuximab Combined With Chemotherapy in the FLEX Trial
32. 9019 POSTER DISCUSSION Safety Analysis of Patient Subgroups Defined by Low and High Tumour Epidermal Growth Factor Receptor (EGFR) Expression in FLEX Study Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Receiving Chemotherapy With or Without Cetuximab as First-Line Therapy
33. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms
34. An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).
35. Use of immunohistochemical evaluation of DNA repair proteins to demonstrate cisplatin response prediction in resected NSCLC squamous cell carcinoma.
36. Rate of hemoglobin (Hb) decline from less than 10 g/dl to less than 9 g/dl in placebo-treated patients (pts) receiving chemotherapy: A pooled analysis of data from six randomized darbepoetin alfa trials.
37. An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).
38. ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy
39. 4IN ESMO RECOMMENDATION 2011: ADVANCED NSCLC
40. Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer
41. Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study
42. D-dimer levels and prediction of overall survival in cancer patients.
43. First-cycle rash as a clinical marker in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy (CT) plus cetuximab: Efficacy by histology.
44. Patient selection for cetuximab in NSCLC: A systematic review of candidate predictive biomarkers.
45. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms
46. Gemcitabin/Vinorelbin sequentiell mit Paclitaxel versus Gemcitabin/Vinorelbin/Cisplatin versus Paclitaxel/Cisplatin beim NSCLC im Stadium IV: eine AIO/AASLC Phase III Studie
47. VEGF and EGFR inhibition: opening a new door to cancer treatment
48. 9161 FLEX study: Prognostic factors in NSCLC
49. 9160 Molecular and clinical biomarkers of outcome with cetuximab: Data from the phase III FLEX study in non-small cell lung cancer (NSCLC)
50. 9009 A meta-analysis of four randomized phase II/III trials adding cetuximab to platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.